Cargando…

Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy

BACKGROUND: Cardiotoxicity from anthracycline-based chemotherapy is an important cause of early and late morbidity and mortality in breast cancer patients. Left ventricular (LV) function is assessed for patients receiving anthracycline-based chemotherapy to identify cardiotoxicity. However, animal s...

Descripción completa

Detalles Bibliográficos
Autores principales: Boczar, Kevin Emery, Aseyev, Olexiy, Sulpher, Jeffrey, Johnson, Christopher, Burwash, Ian G, Turek, Michele, Dent, Susan, Dwivedi, Girish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045517/
https://www.ncbi.nlm.nih.gov/pubmed/27457966
http://dx.doi.org/10.1530/ERP-16-0020
_version_ 1782457130426564608
author Boczar, Kevin Emery
Aseyev, Olexiy
Sulpher, Jeffrey
Johnson, Christopher
Burwash, Ian G
Turek, Michele
Dent, Susan
Dwivedi, Girish
author_facet Boczar, Kevin Emery
Aseyev, Olexiy
Sulpher, Jeffrey
Johnson, Christopher
Burwash, Ian G
Turek, Michele
Dent, Susan
Dwivedi, Girish
author_sort Boczar, Kevin Emery
collection PubMed
description BACKGROUND: Cardiotoxicity from anthracycline-based chemotherapy is an important cause of early and late morbidity and mortality in breast cancer patients. Left ventricular (LV) function is assessed for patients receiving anthracycline-based chemotherapy to identify cardiotoxicity. However, animal studies suggest that right ventricular (RV) function may be a more sensitive measure to detect LV dysfunction. The purpose of this pilot study was to determine if breast cancer patients undergoing anthracycline-based chemotherapy experience RV dysfunction. METHODS: Forty-nine breast cancer patients undergoing anthracycline-based chemotherapy at the Ottawa Hospital between November 2007 and March 2013 and who had 2 echocardiograms performed at least 3months apart were retrospectively identified. Right atrial area (RAA), right ventricular fractional area change (RV FAC) and RV longitudinal strain of the free wall (RV LSFW) were evaluated according to the American Society of Echocardiography guidelines. RESULTS: The majority (48/49) of patients were females with an average age of 53.4 (95% CI: 50.1–56.7years). From baseline to follow-up study, average LV ejection fraction (LVEF) decreased from 62.22 (95% CI: 59.1–65.4) to 57.4% (95% CI: 54.0–60.9) (P=0.04). During the same time period, the mean RAA increased from 12.1cm(2) (95% CI: 11.1–13.0cm(2)) to 13.8cm(2) (95% CI: 12.7–14.9cm(2)) (P=0.02), mean RV FAC decreased (P=0.01) from 48.3% (95% CI: 44.8–51.74) to 42.1% (95% CI: 38.5–45.6%), and mean RV LSFW worsened from −16.2% (95% CI: −18.1 to −14.4%) to −13.81% (95% CI: −15.1 to −12.5%) (P=0.04). CONCLUSION: This study demonstrates that breast cancer patients receiving anthracycline-based chemotherapy experience adverse effects on both right atrial size and RV function. Further studies are required to determine the impact of these adverse effects on right heart function and whether this represents an earlier marker of cardiotoxicity.
format Online
Article
Text
id pubmed-5045517
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-50455172016-10-28 Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy Boczar, Kevin Emery Aseyev, Olexiy Sulpher, Jeffrey Johnson, Christopher Burwash, Ian G Turek, Michele Dent, Susan Dwivedi, Girish Echo Res Pract Research BACKGROUND: Cardiotoxicity from anthracycline-based chemotherapy is an important cause of early and late morbidity and mortality in breast cancer patients. Left ventricular (LV) function is assessed for patients receiving anthracycline-based chemotherapy to identify cardiotoxicity. However, animal studies suggest that right ventricular (RV) function may be a more sensitive measure to detect LV dysfunction. The purpose of this pilot study was to determine if breast cancer patients undergoing anthracycline-based chemotherapy experience RV dysfunction. METHODS: Forty-nine breast cancer patients undergoing anthracycline-based chemotherapy at the Ottawa Hospital between November 2007 and March 2013 and who had 2 echocardiograms performed at least 3months apart were retrospectively identified. Right atrial area (RAA), right ventricular fractional area change (RV FAC) and RV longitudinal strain of the free wall (RV LSFW) were evaluated according to the American Society of Echocardiography guidelines. RESULTS: The majority (48/49) of patients were females with an average age of 53.4 (95% CI: 50.1–56.7years). From baseline to follow-up study, average LV ejection fraction (LVEF) decreased from 62.22 (95% CI: 59.1–65.4) to 57.4% (95% CI: 54.0–60.9) (P=0.04). During the same time period, the mean RAA increased from 12.1cm(2) (95% CI: 11.1–13.0cm(2)) to 13.8cm(2) (95% CI: 12.7–14.9cm(2)) (P=0.02), mean RV FAC decreased (P=0.01) from 48.3% (95% CI: 44.8–51.74) to 42.1% (95% CI: 38.5–45.6%), and mean RV LSFW worsened from −16.2% (95% CI: −18.1 to −14.4%) to −13.81% (95% CI: −15.1 to −12.5%) (P=0.04). CONCLUSION: This study demonstrates that breast cancer patients receiving anthracycline-based chemotherapy experience adverse effects on both right atrial size and RV function. Further studies are required to determine the impact of these adverse effects on right heart function and whether this represents an earlier marker of cardiotoxicity. Bioscientifica Ltd 2016-09 2016-09 /pmc/articles/PMC5045517/ /pubmed/27457966 http://dx.doi.org/10.1530/ERP-16-0020 Text en © 2016 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Research
Boczar, Kevin Emery
Aseyev, Olexiy
Sulpher, Jeffrey
Johnson, Christopher
Burwash, Ian G
Turek, Michele
Dent, Susan
Dwivedi, Girish
Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title_full Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title_fullStr Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title_full_unstemmed Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title_short Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
title_sort right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045517/
https://www.ncbi.nlm.nih.gov/pubmed/27457966
http://dx.doi.org/10.1530/ERP-16-0020
work_keys_str_mv AT boczarkevinemery rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT aseyevolexiy rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT sulpherjeffrey rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT johnsonchristopher rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT burwashiang rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT turekmichele rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT dentsusan rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy
AT dwivedigirish rightheartfunctiondeterioratesinbreastcancerpatientsundergoinganthracyclinebasedchemotherapy